Gene: ZFP36L2

678
BRF2|ERF-2|ERF2|RNF162C|TIS11D
ZFP36 ring finger protein like 2
protein-coding
2p21
Ensembl:ENSG00000152518 MIM:612053 Vega:OTTHUMG00000128642 UniprotKB:P47974
NC_000002.12
PubMed
0   ANCO-SNPs
ND
0   
NA (AD)  NA (ND)   (Frontal_Cortex)
3.175e-1 (AD)  6.161e-1 (ND)

DNA Methylation

There is no related methylation information for this gene.

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
ZFP36L10.858
SH3BP20.803
MSN0.794
SLC39A10.785
CNN30.783
TEAD30.779
TMEM176B0.777
FSTL10.776
TTC380.774
STAT5A0.774

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
CALHM1-0.513
KCNB2-0.491
ABCC12-0.485
PPEF1-0.47
SLC7A4-0.464
CDCA5-0.462
NEUROD6-0.46
GPR61-0.459
STYK1-0.456
PRSS16-0.452

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C5112952,2',4,4'-tetrabromodiphenyl ether"2,2',4,4'-tetrabromodiphenyl ether results in decreased expression of ZFP36L2 mRNA"21394737
C0127962-butenal2-butenal results in decreased expression of ZFP36L2 mRNA20471460
C0095054,4'-diaminodiphenylmethane"4,4'-diaminodiphenylmethane results in increased expression of ZFP36L2 mRNA"18648102
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
D000082AcetaminophenAcetaminophen results in decreased expression of ZFP36L2 mRNA21420995
D000082AcetaminophenAcetaminophen results in increased expression of ZFP36L2 mRNA26690555
D000111AcetylcysteineAcetylcysteine results in increased expression of ZFP36L2 mRNA16084531
D000242Cyclic AMPZFP36L2 protein mutant form results in increased abundance of Cyclic AMP24830504
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ZFP36L2 mRNA20106945|2163298
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of ZFP36L2 mRNA27195522
D004958EstradiolEstradiol results in decreased expression of ZFP36L2 mRNA19167446
D004958EstradiolEstradiol affects the reaction [Dieldrin results in decreased expression of ZFP36L2 mRNA]23041725
D004958EstradiolEstradiol affects the expression of ZFP36L2 mRNA15598610
D004958EstradiolEstradiol results in decreased expression of ZFP36L2 mRNA19484750
C543008bis(4-hydroxyphenyl)sulfone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA28628672
C006780bisphenol Abisphenol A affects the expression of ZFP36L2 mRNA21786754
C006780bisphenol Abisphenol A affects the methylation of ZFP36L2 promoter27334623
C006780bisphenol Abisphenol A affects the expression of ZFP36L2 mRNA21786754
C006780bisphenol Abisphenol A affects the expression of ZFP36L2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of ZFP36L2 gene28505145
C000611646bisphenol F[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA28628672
D0151248-Bromo Cyclic Adenosine Monophosphate8-Bromo Cyclic Adenosine Monophosphate results in increased expression of ZFP36L2 mRNA22079614
D020122tert-Butylhydroperoxidetert-Butylhydroperoxide results in decreased expression of ZFP36L2 mRNA18804290
C584509C646 compoundC646 compound results in decreased expression of ZFP36L2 mRNA26191083
D002104CadmiumCadmium results in increased expression of ZFP36L2 mRNA24376830
D019256Cadmium ChlorideCadmium Chloride results in decreased expression of ZFP36L2 mRNA18804290
D002220CarbamazepineCarbamazepine affects the expression of ZFP36L2 mRNA25979313
D002794Choline[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ZFP36L2 gene20938992
D002994ClofibrateClofibrate affects the expression of ZFP36L2 mRNA16081524
D002994ClofibrateClofibrate results in decreased expression of ZFP36L2 mRNA17585979
C018021cobaltous chloridecobaltous chloride results in decreased expression of ZFP36L2 mRNA19320972|1937684
D005576ColforsinColforsin results in decreased expression of ZFP36L2 mRNA15967414
C030973cupric oxidecupric oxide results in decreased expression of ZFP36L2 mRNA22077320
D016572CyclosporineCyclosporine results in decreased expression of ZFP36L2 mRNA20106945|2556210
D003907DexamethasoneDexamethasone results in increased expression of ZFP36L2 mRNA25047013
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA28628672
D003907Dexamethasone[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA28628672
D003993Dibutyl PhthalateDibutyl Phthalate results in decreased expression of ZFP36L2 mRNA24893172
D003993Dibutyl PhthalateDibutyl Phthalate results in increased expression of ZFP36L2 mRNA21266533
D002945CisplatinCisplatin results in decreased expression of ZFP36L2 mRNA27594783
D002945Cisplatin[Piroxicam co-treated with Cisplatin] results in increased expression of ZFP36L2 mRNA21858171
D002945CisplatinZFP36L2 protein affects the susceptibility to Cisplatin16217747
D002945CisplatinCisplatin results in decreased expression of ZFP36L2 mRNA21151649
D002945CisplatinCisplatin results in decreased expression of ZFP36L2 mRNA22023808
C000944dicrotophosdicrotophos results in increased expression of ZFP36L2 mRNA28302478
C036042dicyclohexyl phthalatedicyclohexyl phthalate affects the expression of ZFP36L2 mRNA26924002
D004026DieldrinDieldrin results in decreased expression of ZFP36L2 mRNA23041725
D004026DieldrinEstradiol affects the reaction [Dieldrin results in decreased expression of ZFP36L2 mRNA]23041725
D004237DiuronDiuron results in decreased expression of ZFP36L2 mRNA21551480
D004317DoxorubicinZFP36L2 mRNA results in decreased susceptibility to Doxorubicin16322897
D004317DoxorubicinZFP36L2 protein affects the susceptibility to Doxorubicin16217747
C045651epigallocatechin gallateepigallocatechin gallate results in increased expression of ZFP36L2 mRNA16084531
C045651epigallocatechin gallate[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFP36L2 mRNA22079256
C540355fenamidonefenamidone results in increased expression of ZFP36L2 mRNA27029645
D005492Folic Acid[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ZFP36L2 gene20938992
C069837fullerene C60fullerene C60 results in increased expression of ZFP36L2 mRNA19167457
D005839GentamicinsGentamicins results in increased expression of ZFP36L2 mRNA22061828
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of ZFP36L2 mRNA20044591
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA28628672
D007213Indomethacin[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA28628672
C051890irinotecanirinotecan metabolite results in decreased expression of ZFP36L2 mRNA15956246
C051890irinotecanirinotecan results in decreased expression of ZFP36L2 mRNA15956246
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bis(4-hydroxyphenyl)sulfone] results in increased expression of ZFP36L2 mRNA28628672
D0150561-Methyl-3-isobutylxanthine[INS protein co-treated with Dexamethasone co-treated with 1-Methyl-3-isobutylxanthine co-treated with Indomethacin co-treated with bisphenol F] results in increased expression of ZFP36L2 mRNA28628672
C561695(+)-JQ1 compound(+)-JQ1 compound results in decreased expression of ZFP36L2 mRNA23086925|2343069
C008261lead acetatelead acetate results in increased expression of ZFP36L2 mRNA21829687
C045463leflunomideleflunomide results in increased expression of ZFP36L2 mRNA28988120
D008627Mercuric ChlorideMercuric Chloride affects the expression of ZFP36L2 mRNA20353558
D008715Methionine[Methionine deficiency co-treated with Choline deficiency co-treated with Folic Acid deficiency] results in decreased methylation of ZFP36L2 gene20938992
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of ZFP36L2 mRNA28001369
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of ZFP36L2 mRNA26011545
D018817N-Methyl-3,4-methylenedioxyamphetamine"N-Methyl-3,4-methylenedioxyamphetamine results in decreased expression of ZFP36L2 mRNA"20188158
C406082monomethylarsonous acidmonomethylarsonous acid results in decreased expression of ZFP36L2 mRNA22108045
C017096n-butoxyethanoln-butoxyethanol results in increased expression of ZFP36L2 mRNA19812364
C028007nickel monoxidenickel monoxide results in increased expression of ZFP36L2 mRNA19167457
C029938nickel sulfatenickel sulfate results in increased expression of ZFP36L2 mRNA18651567
D009966OrphenadrineOrphenadrine affects the expression of ZFP36L2 mRNA23665939
D010100OxygenOxygen deficiency results in increased expression of ZFP36L2 mRNA24205000
D017239PaclitaxelZFP36L2 protein affects the susceptibility to Paclitaxel16217747
C496932panobinostat"[NOG protein co-treated with panobinostat co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C496932panobinostatpanobinostat results in increased expression of ZFP36L2 mRNA26272509
C016030pantogabpantogab results in increased expression of ZFP36L2 mRNA17379144
D010416PentachlorophenolPentachlorophenol results in increased expression of ZFP36L2 mRNA24642059
D010634PhenobarbitalPhenobarbital affects the expression of ZFP36L2 mRNA23091169
C006253pirinixic acid[pirinixic acid binds to and results in increased activity of PPARA protein] which results in decreased expression of ZFP36L2 mRNA19710929
C006253pirinixic acidpirinixic acid results in increased expression of ZFP36L2 mRNA18301758|1844570
D010894Piroxicam[Piroxicam co-treated with Cisplatin] results in increased expression of ZFP36L2 mRNA21858171
C027373potassium chromate(VI)[potassium chromate(VI) co-treated with epigallocatechin gallate] results in increased expression of ZFP36L2 mRNA22079256
C027373potassium chromate(VI)potassium chromate(VI) results in increased expression of ZFP36L2 mRNA22079256
D011441PropylthiouracilPropylthiouracil results in increased expression of ZFP36L2 mRNA24780913
C513428pyrachlostrobinpyrachlostrobin results in increased expression of ZFP36L2 mRNA27029645
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of ZFP36L2 mRNA25895662
D012834SilverSilver results in decreased expression of ZFP36L2 mRNA26014281
C017947sodium arsenitesodium arsenite results in decreased expression of ZFP36L2 mRNA25879800
D018038Sodium SeleniteSodium Selenite results in increased expression of ZFP36L2 mRNA18175754
D012999SomanSoman results in increased expression of ZFP36L2 mRNA19281266
D013629TamoxifenTamoxifen affects the expression of ZFP36L2 mRNA20937368
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ZFP36L2 mRNA20106945
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of ZFP36L2 mRNA21632981
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of ZFP36L2 mRNA19770486|2629044
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of ZFP36L2 mRNA22298810
D013750TetrachloroethyleneTetrachloroethylene results in increased expression of ZFP36L2 mRNA28973375
D013853ThioacetamideThioacetamide results in increased expression of ZFP36L2 mRNA23411599
D013853ThioacetamideThioacetamide results in increased methylation of ZFP36L2 promoter27914986
C483909torcetrapibtorcetrapib results in increased expression of ZFP36L2 mRNA23228038
C496197trans-10,cis-12-conjugated linoleic acid"trans-10,cis-12-conjugated linoleic acid results in decreased expression of ZFP36L2 mRNA"17951470
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
C012589trichostatin Atrichostatin A affects the expression of ZFP36L2 mRNA28542535
C012589trichostatin Atrichostatin A results in decreased expression of ZFP36L2 mRNA24935251
C012589trichostatin Atrichostatin A results in increased expression of ZFP36L2 mRNA24935251|2627250
D014302Trinitrobenzenesulfonic AcidTrinitrobenzenesulfonic Acid results in increased expression of ZFP36L2 mRNA17982090
C016805tris(1,3-dichloro-2-propyl)phosphate"tris(1,3-dichloro-2-propyl)phosphate results in decreased expression of ZFP36L2 mRNA"26179874
C057693troglitazonetroglitazone results in decreased expression of ZFP36L2 mRNA28973697
C406224valdecoxibvaldecoxib results in increased expression of ZFP36L2 mRNA24136188
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of ZFP36L2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of ZFP36L2 mRNA25979313
D014635Valproic AcidValproic Acid results in decreased expression of ZFP36L2 mRNA24935251|2915479
D014635Valproic AcidValproic Acid results in increased expression of ZFP36L2 mRNA24383497|2493525
D014635Valproic AcidValproic Acid affects the expression of ZFP36L2 mRNA17292431
D014747VinblastineZFP36L2 protein affects the susceptibility to Vinblastine16217747
D024483Vitamin K 3Vitamin K 3 affects the expression of ZFP36L2 mRNA20044591
C088658zoledronic acidzoledronic acid results in increased expression of ZFP36L2 mRNA20977926

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA binding-ISM19274049  
GO:0003677DNA binding-IEA-  
GO:0003700DNA-binding transcription factor activity-TAS7835719  
GO:0003723RNA binding-HDA22658674  
GO:0003730mRNA 3'-UTR binding-IBA21873635  
GO:0005515protein binding-IPI25106868  
GO:0017091AU-rich element binding-IDA20506496  
GO:0035925mRNA 3'-UTR AU-rich region binding-IDA25106868  
GO:0046872metal ion binding-IEA-  
GO ID GO Term Qualifier Evidence PubMed
GO:0000288nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay-IEA-  
GO:0006357regulation of transcription by RNA polymerase II-IEA-  
GO:0006402mRNA catabolic process-ISS-  
GO:0008283cell proliferation-TAS7835719  
GO:0009611response to wounding-IDA27182009  
GO:0030097hemopoiesis-ISS-  
GO:0033077T cell differentiation in thymus-ISS-  
GO:0035019somatic stem cell population maintenance-ISS-  
GO:0043488regulation of mRNA stability-IMP25106868  
GO:0043488regulation of mRNA stability-ISS-  
GO:0044344cellular response to fibroblast growth factor stimulus-IDA20166898  
GO:0045577regulation of B cell differentiation-ISS-  
GO:0045599negative regulation of fat cell differentiation-ISS-  
GO:0048103somatic stem cell division-ISS-  
GO:0060216definitive hemopoiesis-ISS-  
GO:00611583'-UTR-mediated mRNA destabilization-IBA21873635  
GO:00611583'-UTR-mediated mRNA destabilization-IMP25106868  
GO:00611583'-UTR-mediated mRNA destabilization-ISS-  
GO:0070371ERK1 and ERK2 cascade-IDA25106868  
GO:0071356cellular response to tumor necrosis factor-IDA20166898  
GO:0071364cellular response to epidermal growth factor stimulus-IDA20166898  
GO:0071385cellular response to glucocorticoid stimulus-IDA20166898  
GO:0071560cellular response to transforming growth factor beta stimulus-IDA20166898  
GO:0097011cellular response to granulocyte macrophage colony-stimulating factor stimulus-IDA20166898  
GO:1900153positive regulation of nuclear-transcribed mRNA catabolic process, deadenylation-dependent decay-ISS-  
GO:1901991negative regulation of mitotic cell cycle phase transition-ISS-  
GO:2000737negative regulation of stem cell differentiation-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0005634nucleus-ISS-  
GO:0005737cytoplasm-ISS-  
GO:0005829cytosol-IBA21873635  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal